Latest news with #MTB
Yahoo
4 days ago
- Business
- Yahoo
M&T Bank (MTB) Down 0.8% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for M&T Bank Corporation (MTB). Shares have lost about 0.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is M&T Bank due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for M&T Bank Corporation before we dive into how investors and analysts have reacted as of late. M&T Bank Q2 Earnings Top Estimates on Higher Non-Interest Income M&T Bank's second-quarter 2025 adjusted net operating earnings per share of $4.28 beat the Zacks Consensus Estimate of $4.04. The bottom line compared favorably with earnings of $3.79 per share in the year-ago quarter. Results were aided by higher non-interest income and lower provisions. Also, a rise in loan balances was another positive. However, a fall in net interest income, rising expenses and lower deposits were headwinds. Net income available to common shareholders was $679 million, up 8.5% from the prior-year quarter. Quarterly Revenues & Expenses Rise Y/Y Quarterly revenues were $2.40 billion, marginally surpassing the Zacks Consensus Estimate of $2.39 billion. Further, the reported figure increased 4.1% year over year. NII (tax equivalent) declined marginally year over year to $1.72 billion. Total non-interest income was $683 million, up 17% year over year. The rise was driven by an increase in almost all components. Total non-interest expenses were $1.34 billion, up 3% year over year. The increase was due to higher salaries and employee benefits costs, equipment and net occupancy expenses, and outside data processing and software costs. The efficiency ratio was 55.2%, down from 55.3% in the year-earlier quarter. A lower ratio indicates a rise in profitability. Loan Balance Increases, Deposits Decrease Total loans were $136.1 billion as of June 30, 2025, up 1.1% from the prior quarter. Total deposits fell marginally sequentially to $164.5 billion. Credit Quality Improves Net charge-offs decreased 21.2% to $108 million from the prior-year quarter. The company recorded a provision for credit losses of $125 million, down 16.7% from the year-ago quarter. Non-performing assets declined 22.1% year over year to $1.60 billion. The ratio of non-accrual loans to total net loans was 1.16%, which declined year over year from 1.50%. Capital Position Mixed & Profitability Ratios Improve Y/Y M&T Bank's estimated Common Equity Tier 1 ratio was 10.98%, down from 11.45% as of second-quarter 2024. The tangible equity per share was $112.48, up from $102.42 in the second quarter of 2024. The company's return on average tangible assets (annualized) and average tangible common shareholder equity were 1.44% and 15.54% respectively, compared with 1.31% and 15.27% in the prior-year quarter. Capital Distribution Update The company repurchased 6.07 million shares of its common stock in accordance with its capital plan for $175.93 million, including the share repurchase excise tax, in the second quarter of 2025. Outlook 2025 Management projects NII (tax equivalent basis) to be $7.05-$7.15 billion. The company expects NIM to be in the mid to high 3.60%. Non-interest income is anticipated between $2.5 billion and $2.6 billion. Expenses (GAAP), including intangible amortization, are expected to be $5.4-$5.5 billion. The company expects average loan and lease balances to be $135 billion to $137 billion. Average total deposit balances are anticipated to be $162-$164 billion. The NCO rate is projected to be 40 bps. CET 1 ratio is expected to be 10.75% to 11%. The tax rate is anticipated to be 24.5% for 2025. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a upward trend in fresh estimates. VGM Scores Currently, M&T Bank has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the second quintile for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, M&T Bank has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Performance of an Industry Player M&T Bank belongs to the Zacks Banks - Major Regional industry. Another stock from the same industry, The Bank of New York Mellon Corporation (BK), has gained 5.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025. The Bank of New York Mellon reported revenues of $5.03 billion in the last reported quarter, representing a year-over-year change of +9.4%. EPS of $1.94 for the same period compares with $1.51 a year ago. The Bank of New York Mellon is expected to post earnings of $1.73 per share for the current quarter, representing a year-over-year change of +13.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.9%. The Bank of New York Mellon has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report M&T Bank Corporation (MTB) : Free Stock Analysis Report The Bank of New York Mellon Corporation (BK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Effettua l'accesso per consultare il tuo portafoglio
Business Wire
7 days ago
- Health
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
Toronto Star
13-08-2025
- Business
- Toronto Star
ExGen Resources and MTB Metals Enter into Non-Binding Letter of Intent to Merge, Creating a Copper, Gold and Lithium Exploration and Development Company
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) — ExGen Resources Inc. (TSX.V: EXG; OTC: BXXRF) ('ExGen', the 'Company') and MTB Metals Corp. (TSXV: MTB, OTCQB: MBYMF, Frankfurt: M9U) ('MTB'): ExGen and MTB are pleased to announce that they have entered into an non-binding letter of intent dated August 12, 2025 (the 'LOI'). The LOI contemplates terms and conditions subject to: (i) the negotiation and finalization of the definitive agreement (the 'Definitive Agreement') between the ExGen and MTB; and (ii) the terms of a potential business combination pursuant to which ExGen and MTB will combine their operations, business, assets and properties (the 'Proposed Transaction'). The Proposed Transaction will be subject to approval by MTB shareholders, court, and TSX Venture Exchange (the 'TSX-V') approvals, among others, and other closing conditions customary in transactions of this nature. The Proposed Transaction will be an Arm's Length Transaction for both companies under the policies of the TSX-V.
Yahoo
12-08-2025
- Automotive
- Yahoo
Leatt Corp Announces Share Repurchase Program
CAPE TOWN, South Africa, Aug. 12, 2025 /PRNewswire/ -- Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe protective equipment for MOTO, MTB, and a wide range of extreme and high-velocity sports, today announced that its Board of Directors has authorized a share repurchase program of up to $750,000 of the Company's outstanding common stock. "This share repurchase program reflects our confidence in the future outlook of our business, the soundness of our balance sheet, and the overall strength of the Leatt organization," said Sean Macdonald, Chief Executive Officer. "We believe that this program provides an opportunity to enhance long-term shareholder value, while delivering on our mission of developing and manufacturing cutting-edge protective products for participants in extreme sports." Repurchases may be made from time to time at the discretion of the Board of Directors through open-market transactions in accordance with applicable securities laws. The repurchase program expires on December 31, 2025, and can be suspended or discontinued at any time prior to the expiration date. No shares have been repurchased under the program to date. There can be no assurance as to the timing or number of shares of any repurchases, if any. About Leatt Corp Driven by the science of thrill, Leatt Corporation develops head-to-toe personal protective gear for various sports, with a focus on mountain biking and extreme motorsports. This includes the award-winning Leatt-Brace®, a neck brace system considered the gold standard for neck protection when worn in conjunction with a helmet. Leatt products are designed for participants in extreme sports that use motorcycles, bicycles, mountain bikes, all-terrain vehicles, snowmobiles, and other open-air vehicles. For more information, visit Follow Leatt® on Facebook, Twitter, and Instagram. Forward-looking Statements This press release may contain forward-looking statements regarding Leatt Corporation (the "Company") within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding the significance of the Company's share repurchase plan and its ability to enhance the long-term value of the Company's securities; the general ability of the Company to achieve its commercial objectives, including its continued development and manufacturing of cutting-edge protective products; the business strategy, plans and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," "anticipates," "seeks," "should," "could," "intends," or "projects" or similar expressions, and involve known and unknown risks and uncertainties. These statements are based upon the Company's current expectations and speak only as of the date hereof. Any indication of the merits of a claim does not necessarily mean the claim will prevail at trial or otherwise. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those listed in other reports posted on The OTC Markets Group, Inc. View original content: SOURCE Leatt Corporation
Yahoo
17-07-2025
- Business
- Yahoo
MTB Q1 Deep Dive: Margin Expansion and Loan Mix Offset Deposit and CRE Headwinds
Regional banking company M&T Bank (NYSE:MTB) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 4.1% year on year to $2.40 billion. Its GAAP profit of $4.24 per share was 6.3% above analysts' consensus estimates. Is now the time to buy MTB? Find out in our full research report (it's free). M&T Bank (MTB) Q2 CY2025 Highlights: Revenue: $2.40 billion vs analyst estimates of $2.38 billion (4.1% year-on-year growth, 0.6% beat) EPS (GAAP): $4.24 vs analyst estimates of $3.99 (6.3% beat) Market Capitalization: $30.14 trillion StockStory's Take M&T Bank's first quarter results did not meet Wall Street's expectations, with management attributing the outcome primarily to a combination of lower commercial real estate (CRE) loan balances, seasonally lower deposit levels, and a modest decline in net interest income. CFO Daryl Bible highlighted that net interest margin improved 8 basis points, even as average loans declined. He pointed to disciplined deposit pricing, a reduction in higher-cost funding, and strong performance in fee-generating businesses such as mortgage banking and trust services. Additionally, asset quality improved, with lower net charge-offs and a reduction in criticized CRE balances. Management acknowledged a dynamic environment, noting that customer uncertainty around tariffs and broader economic trends led to business investment delays and a pause in some acquisition activity. Looking ahead, M&T Bank's guidance is shaped by a cautious stance on CRE loan origination and a focus on maintaining strong liquidity and capital levels. Management expects loan growth to remain muted, particularly in CRE, while C&I (commercial and industrial) and consumer lending are projected to offset some of these headwinds. CFO Daryl Bible stated, "We remain focused on growing customer deposits at a reasonable cost, while also considering loan growth." The company is also monitoring the impact of macroeconomic uncertainties—especially tariffs and regulatory changes—on customer activity and credit quality. Management emphasized flexibility in expense management and signaled ongoing investments in technology and risk management capabilities to support long-term profitability. Key Insights from Management's Remarks Management credited the quarter's margin expansion to deposit cost discipline and a shift in loan mix, while acknowledging ongoing competitive pressures in CRE and muted deposit growth. Deposit cost management: The bank achieved a decline in interest-bearing deposit costs as it reduced reliance on brokered and wholesale funding, helping offset the impact of lower average deposits and providing a lift to net interest margin. CRE portfolio runoff: CRE balances declined significantly due to elevated payoffs and competition from other lenders, with management reiterating a disciplined approach to new originations and a focus on reducing riskier office exposures. C&I and consumer loan growth: Growth in commercial and industrial (C&I) and consumer portfolios partially offset the CRE decline, supported by momentum in fund banking, corporate institutional lending, and indirect auto finance. Fee income momentum: Non-interest income, including mortgage banking and trust services, remained resilient, and management expects further growth as new subservicing relationships ramp up and service charges perform well. Expense control and capital return: Management continued to tightly manage expenses, highlighted flexibility to adjust spending if needed, and executed substantial share repurchases, while maintaining a CET1 ratio above 11%. Drivers of Future Performance M&T Bank's outlook hinges on balancing muted CRE loan demand, deposit growth, and adaptable expense management amid an uncertain macroeconomic backdrop. CRE loan headwinds: Management expects commercial real estate balances to bottom out by year-end, with muted originations due to competitive pricing and customer hesitancy. The focus remains on selective growth in multifamily and industrial segments to reduce exposure to riskier office loans. Deposit growth and pricing: The company anticipates deposit balances to recover from seasonal lows, with an emphasis on attracting stable, low-cost deposits. CFO Daryl Bible noted that higher deposit levels would be deployed to pay down more expensive liabilities or increase liquidity, depending on loan demand. Expense flexibility and risk management: Management emphasized the ability to adjust expenses if revenue growth slows, with ongoing investments in systems, automation, and risk controls. The bank is closely monitoring portfolios such as retail trade, manufacturing, and non-profits for signs of stress, and remains prepared to adapt if the macroeconomic environment deteriorates. Catalysts in Upcoming Quarters In the coming quarters, the StockStory team will focus on (1) stabilization and eventual growth of CRE and C&I loan balances, (2) trends in deposit growth and the cost of funds, and (3) the trajectory of fee income as mortgage subservicing and trust businesses scale. Monitoring regulatory developments and any shifts in credit quality within key loan portfolios will also be crucial for assessing M&T Bank's performance. M&T Bank currently trades at $191.43, down from $197.03 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free). High Quality Stocks for All Market Conditions Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
